Inari Medical Stock News

By Chris Wack Inari Medical Inc. shares were down 17% to $81.13 after the company said it began an underwritten public offering of 2 million common shares….

IRVINE, Calif., March 10, 2022 (GLOBE NEWSWIRE) -- Inari Medical, Inc. (NASDAQ: NARI) (“Inari”), a medical device company focused on developing products to treat and transform the lives of patie

Inari Medical's (NARI) fourth-quarter results benefit from significant progress made across all of its growth drivers.

In last trading session, Inari Medical Inc. (NASDAQ:NARI) saw 0.81 million shares changing hands with its beta currently measuring 0. Company’s recent per share price level of $85.48 trading at $0.16 or 0.19% at ring of the bell on the day assigns it a market valuation of $4.40B. That closing price of NARI’s stock is … Inari Medical Inc. (NASDAQ:NARI) Has Already Recovered 25.87%, But Another -49.06% Drop Cannot Be Ruled Out. Read More »

Inari Medical Inc''s (NASDAQ: NARI ) Q4 revenue was $83.2 million , up 14% sequentially and 71% Y/Y, beating the consensus of $78.16 million. The sequential growth was driven by continued U.S. commercial expansion and new product introductions. The gross margin was 90.1% compared to 92.4% a year ago, modestly lower … Full story available on Benzinga.com

NARI earnings call for the period ending December 31, 2021.

NARI earnings call for the period ending December 31, 2021.

Inari Medical, Inc. (NARI) CEO Bill Hoffman on Q4 2021 Results - Earnings Call Transcript

Inari Medical press release (NARI): Q4 GAAP EPS of $0.02 in-line.Revenue of $83.22M (+71.2% Y/Y) beats by $3.45M.Outlook: For the full year 2022, revenue of $350 million to $360…

IRVINE, Calif., Feb. 23, 2022 (GLOBE NEWSWIRE) -- Inari Medical, Inc. (NASDAQ: NARI) (“Inari”), a medical device company with a mission to treat and transform the lives of patients suffering fro

IRVINE, Calif., Feb. 23, 2022 (GLOBE NEWSWIRE) -- Inari Medical, Inc. (NASDAQ: NARI) (“Inari”), a medical device company with a mission to treat and…

Here's a roundup of top developments in the biotech space over the last 24 hours. Stocks In Focus Kodiak's Wet AMD Treatment KSI-301 Did Not Meet Primary Endpoint In Phase 2b/3 Study Kodiak Sciences

Inari Medical (NASDAQ:NARI) is scheduled to announce Q4 earnings results on Wednesday, Feb. 23, after market close.The consensus EPS estimate is $0.03

Biotech stock extended lower for a second straight week as risk aversion continued to pressure stocks amid geopolitical tensions and macroeconomic worries. On the regulatory front, the Food and Drug A